Welcome to the Starpharma Investor CentreStarpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
 |
Latest News & Announcements
Positive AZD0466 clinical data presented by AstraZeneca (ASX Announcement)
Dec 13th, 2022
Starpharma today announces preliminary AZD0466 clinical trial results from the ongoing Phase 1/2 trial in patients with advanced relapsed/refractory leukemia (NCT04865419), presented by Starpharma’s partner AstraZeneca at the 2022 American Society of Hematology (ASH) Annual Meeting today.
Read More
Starpharma presents additional clinical data for DEP® cabazitaxel in prostate cancer (ASX Announcement)
Sep 12th, 2022
Starpharma announces additional results from the mCRPC cohort of its Phase 2 DEP® cabazitaxel trial, following completion of dosing in this cohort. Treatment with DEP® cabazitaxel showed a number of key advantages compared to published data for conventional cabazitaxel, including superior efficacy, as measured by longer PFS, and a lower incidence of key side effects, despite this patient cohort being relatively more heavily pre-treated.
Read More
Reports & Presentations
Click here for financial reports archive
Resignation of CFO / Company Secretary
Dec 21st, 2022
Starpharma today announces that after nearly 17 years with the Company, including 14 years as Chief Financial Officer (CFO), Mr Nigel Baade, has advised of his intention to leave Starpharma in early 2023 to pursue new professional opportunities.
Read More
Positive AZD0466 clinical data presented by AstraZeneca (ASX Announcement)
Dec 13th, 2022
Starpharma today announces preliminary AZD0466 clinical trial results from the ongoing Phase 1/2 trial in patients with advanced relapsed/refractory leukemia (NCT04865419), presented by Starpharma’s partner AstraZeneca at the 2022 American Society of Hematology (ASH) Annual Meeting today.
Read More